𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease

✍ Scribed by Kanthi Yalamanchili; Sherif Saadeh; Göran B. Klintmalm; Linda W. Jennings; Gary L. Davis


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
262 KB
Volume
16
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis


Nonalcoholic steatohepatitis (NASH) may account for many cases of cryptogenic cirrhosis. If so, then steatosis might recur after liver transplantation. Two thousand fifty-two patients underwent primary liver transplantation for chronic liver disease between 1986 and 2004. Serial liver biopsy samples were assessed for steatosis and fibrosis. Two hundred fifty-seven patients (12%) had a pretransplant diagnosis of cryptogenic cirrhosis (239) or NASH (18). Fatty liver developed in 31% and was more common when the pretransplant diagnosis was NASH (45% at 5 years versus 23% for cryptogenic cirrhosis, P ¼ 0.007). NASH developed in only 4% and occurred exclusively when steatosis had already occurred. Steatosis after liver transplantation was associated with the baseline body weight and body mass index by univariate analyses, but no pretransplant or posttransplant characteristic independently predicted steatosis after liver transplantation because obesity was so common in all groups. Five percent and 10% developed bridging fibrosis or cirrhosis after 5 and 10 years, respectively, and this was more common after NASH (31%) than in those who developed steatosis alone (6%) or had no fat (3%, P ¼ 0.002). One-, 5-, and 10-year survival was the same in patients who underwent transplantation for cryptogenic cirrhosis or NASH (86%, 71%, and 56%) and in patients who underwent transplantation for other indications (86%, 71%, and 53%; not significant), but death was more often due to cardiovascular disease and less likely from recurrent liver disease. In conclusion, fatty liver is common after liver transplantation for cryptogenic cirrhosis or NASH but is twice as common in the latter group; this suggests that some cryptogenic cirrhosis, but perhaps not all, is caused by NASH. Posttransplant NASH is unusual, and steatosis appears to be a prerequisite. Advanced fibrosis is uncommon, and survival is the same as that of patients who undergo transplantation for other causes.


📜 SIMILAR VOLUMES


Nonalcoholic fatty liver disease and liv
✍ Paul Angulo 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB

Nonalcoholic fatty liver disease affects a substantial proportion of the general population worldwide. This high prevalence of nonalcoholic fatty liver disease has important consequences in the donor selection process for liver transplantation, and in the posttransplant period given the high recurre

De novo nonalcoholic fatty liver disease
✍ Suk Seo; Kalyani Maganti; Manjit Khehra; Rajendra Ramsamooj; Alexander Tsodikov; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

Hepatic steatosis is a recognized problem in patients after orthotopic liver transplant (OLT). However, de novo development of nonalcoholic fatty liver disease (NAFLD) has not been well described. The aim of this study was to determine the prevalence and predictors of de novo NAFLD after OLT. A retr

De Novo nonalcoholic fatty liver disease
✍ Manal F. Abdelmalek; Anna Mae Diehl 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

Achieving long-term graft survival and mortality is the primary goal of liver transplantation (LT). However, disease recurrence remains a stumbling block, especially among patients with hepatitis C. In such patients, worse outcomes may be associated with comorbidities (i.e., hyperlipidemia, hyperten

Recurrent familial hypobetalipoproteinem
✍ Noboru Harada; Yuji Soejima; Akinobu Taketomi; Tomoharu Yoshizumi; Hideaki Uchiy 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB

Familial hypobetalipoproteinemia (FHBL) is one of the causes of nonalcoholic steatohepatitis (NASH) and a codominant disorder. Patients heterozygous for FHBL may be asymptomatic, although they demonstrate low plasma levels of low-density lipoprotein (LDL) cholesterol and apolipoprotein B. Here we re